Skip to main content

GlaxoSmithKline-gsk-logo

Lupus is a poorly-understood autoimmune disorder that is characterised by joint pain and swelling, rashes on the skin and extreme fatigue, with some patients experiencing intermittent flare-ups which can lead to severe and even life-threatening symptoms.

GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product – which was approved as in one-hour infusion formulation for SLE in 2011, the first new therapy for the disease in five decades.

{iframe}http://www.pmlive.com/pharma_news/gsk_and_az_drugs_impress_in_lupus_trials_862181{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.